OncoZenge AB (publ) announced that the company has filed a new patent application with the Swedish Patent and Registration Office (PRV). The patent strengthens the protection of the second generation of BupiZenge(TM) and the innovations made in connection with the recent reformulation. The new patent will provide strengthened IP protection for strategic partners and licensees upon approval.

In line with OncoZenge's strategy, the company has assessed the opportunities for complementary patents that further strengthen the protection for the second generation formulation of BupiZenge?? specifically, as well as for pain-relieving lozenges in general. After thorough analysis of these opportunities, and in consultation with experts and patent attorneys, the company announces that a new patent application has been filed.

The patent application is based on insights and innovations made in the work with new formulations of the product, and was submitted to the Swedish Patent and Registration Office on February 7, 2024. With the new patent application, BupiZenge(as pain reliever for oral mucositis, or future variants of BupiZenge for other indications, will be patent protected until 2045, subject to approval. BupiZenge(TM) - Potential to be the leading treatment for oral pain.